TR201904215T4 - Bakteriyel yapay kromozomlar. - Google Patents
Bakteriyel yapay kromozomlar. Download PDFInfo
- Publication number
- TR201904215T4 TR201904215T4 TR2019/04215T TR201904215T TR201904215T4 TR 201904215 T4 TR201904215 T4 TR 201904215T4 TR 2019/04215 T TR2019/04215 T TR 2019/04215T TR 201904215 T TR201904215 T TR 201904215T TR 201904215 T4 TR201904215 T4 TR 201904215T4
- Authority
- TR
- Turkey
- Prior art keywords
- cdna
- bac
- rna
- vaccine
- viral
- Prior art date
Links
- 210000004436 artificial bacterial chromosome Anatomy 0.000 title claims abstract 27
- 239000002299 complementary DNA Substances 0.000 claims abstract 28
- 230000003612 virological effect Effects 0.000 claims abstract 19
- 241001493065 dsRNA viruses Species 0.000 claims abstract 17
- 229960005486 vaccine Drugs 0.000 claims abstract 14
- 230000002238 attenuated effect Effects 0.000 claims abstract 9
- 230000001580 bacterial effect Effects 0.000 claims abstract 8
- 230000003321 amplification Effects 0.000 claims abstract 4
- 210000004027 cell Anatomy 0.000 claims abstract 4
- 230000001939 inductive effect Effects 0.000 claims abstract 4
- 210000004962 mammalian cell Anatomy 0.000 claims abstract 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract 4
- 208000015181 infectious disease Diseases 0.000 claims abstract 3
- 230000002458 infectious effect Effects 0.000 claims abstract 3
- 108020000999 Viral RNA Proteins 0.000 claims abstract 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 5
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims 3
- 102000018697 Membrane Proteins Human genes 0.000 claims 3
- 108010052285 Membrane Proteins Proteins 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 210000002845 virion Anatomy 0.000 claims 3
- 241000710831 Flavivirus Species 0.000 claims 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- 241000282693 Cercopithecidae Species 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 241000724709 Hepatitis delta virus Species 0.000 claims 1
- 241001112094 Hepevirus Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 241000710778 Pestivirus Species 0.000 claims 1
- 241000709664 Picornaviridae Species 0.000 claims 1
- 102000017143 RNA Polymerase I Human genes 0.000 claims 1
- 108010013845 RNA Polymerase I Proteins 0.000 claims 1
- 102000009572 RNA Polymerase II Human genes 0.000 claims 1
- 108010009460 RNA Polymerase II Proteins 0.000 claims 1
- 102000014450 RNA Polymerase III Human genes 0.000 claims 1
- 108010078067 RNA Polymerase III Proteins 0.000 claims 1
- 208000009341 RNA Virus Infections Diseases 0.000 claims 1
- 108700010756 Viral Polyproteins Proteins 0.000 claims 1
- 241000710772 Yellow fever virus Species 0.000 claims 1
- 229940124926 Yellow fever virus vaccine Drugs 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000003362 replicative effect Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 229940051021 yellow-fever virus Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C12N15/69—Increasing the copy number of the vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Buluş, bir aşının hazırlanması için bir bakteriyel yapay kromozomun (BAC) kullanımı ile ilgili olup, burada BAC: BAC'ın bakteri hücresi başına 10'dan fazla kopyaya amplifikasyonu için bir indüklenebilir bakteriyel ori sekansı ve bir atenüe RNA virüsü genomunun bir cDNA'sını içeren ve memeli hücrelerinde söz konusu viral cDNA'nın cis-regülatör elemanlarını içern ve transkribe edilmiş RNA'nın bulaşıcı viral RNA virüsüne işlenmesi için bir viral ekspresyon kaseti içermektedir. Şekil 10
Claims (13)
1. Bir asi olarak kullanima yönelik bir bakteriyel yapay kromozom (BAC) olup, özelligi; BAC'in: - söz konusu BAC'in bakteri hücresi basina lO'dan fazla kopyaya amplifikasyonu için bir indüklenebilir bakteriyel ori sekansi ve - bir atenüe RNA virüsü genomunun bir cDNA'sini içeren ve memeli hücrelerinde söz konusu viral cDNA'nin cis-regülatör elemanlarini içern ve transkribe edilmis RNA'nin bulasici RNA virüsüne islenmesi için bir Viral ekspresyon kaseti içermesidir.
2. Bir asi olarak kullanima yönelik, Istem l'e göre BAC olup, özelligi; bir atenüe RNA virüsü genomunun söz konusu cDNA'sinin bir RNA virüsü genomunun bir kimerik viral cDNA yapisi olmasi, burada bir heterolog DNA sekansinin eklenmis olmasi veya burada bir dogal Viral sekansin silinmis, ucu kesilmis veya mutasyona ugramis olmasidir.
3. Bir asi olarak kullanima yönelik, Istem l'e göre BAC olup, özelligi; söz konusu viral ekspresyon kasetinin: bir pozitif-sarmalli RNA virüsü genomunun bir cDNA'sini, söz konusu cDNA'nin transkripsiyonunu baslatmak için söz konusu cDNA'nin 5' ucundan önce gelen bir RNA polimeraz tahrikli promotörünü ve söz konusu viral cDNA'nin ayarlanan bir pozisyonda RNA transkriptini yarmak için söz konusu cDNA'nin 3' ucunu takip eden RNA'nin kendi kendini yarmasi bir elemani, tercihen hepatit delta virüsünün genomik ribozomunun cDNA'sini içermesidir.
4. Bir asi olarak kullanima yönelik, Istem 3'e göre BAC olup, özelligi; pozitif sarmalli RNA, virüsünün flavivirüsler, hepasivirüsler, pestivirüsler, togavirüsler, pikornavirüsler, koronavirüsler, hepevirüsler ve kalisivirüslerden olusan gruptan seçilmesidir.
5. bir asi olarak kullanima yönelik, Istemler 1 ila 4'ten herhangi birine göre BAC olup, özelligi; söz konusu Viral ekspresyon kasetinin bir sarihumma virüsünün bir cDNA'sini, tercihen sarihumma Virüsü asisinin canli atenüe YFV-l7'D'sinin cDNA'sinni içermesidir.
6. RNA virüslerine karsi bir asi olarak kullanima yönelik, Istem l'e göre BAC olup, özelligi; söz konusu Viral ekspresyon kasetinin negatif sarmalli RNA virüslerinin, çift sarmalli RNA virüslerinin veya ambisens RNA virüslerinin grubuna ait olan bir virüsün bir cDNA'sini içermesidir.
7. Bir asi olarak kullanima yönelik, Istemler l ila 6'dan herhangi birine göre BAC olup, özelligi; söz konusu bakteriyel yapay kromozomun söz konusu bakteriyel yapay kromozomu mayaya tasimak ve burada korumak için bir maya otonom olarak çogalan sekansi, tercihen Zu plazmid orijini veya ARSl (otonom olarak
8. Bir asi olarak kullanima yönelik, Istem 3'e göre BAC olup, özelligi; söz konusu RNA polimeraz tahrikli promotörün tercihen Sitomegalovirüs Erken (CMV-IE) promotöründen, Maymun Virüsü 40 promotöründen seçilen bir RNA polimeraz II promotörü olmasidir veya burada söz konusu RNA polimeraz tahrikli promotörün bir RNA polimeraz I veya III promotörü olmasidir.
9. Bir asi olarak kullanima yönelik, Istem 5'e göre BAC olup, özelligi; Viral ekspresyon kasetinin canli atenüe YFV-17D asisinin bir cDNA'sini içermesi, burada Viryon yüzey proteinleri içinr cDNA› sekansi kodlamasininr birininr veya daha fazlasinin silinmesi, ucunun kesilmesi ya da nmtasyona ugramasi böylece YFV-17D'nin bu fonksiyonel viryon yüzey proteini eksprese edilmemesi ve burada bir heterolog protein için CDNA sekansi kodlamasinin YFV-17D cDNA'ya eklenmesidir.
10. Bir asi olarak kullanima yönelik, Istem 9'a göre BAC olup, özelligi; söz konusu heterolog proteinin bir flavivirüsün bir viryon yüzey proteini olmasidir.
11. Bir asi olarak kullanima yönelik, Istem 9 veya lO'a göre BAC olup, özelligi; söz konusu viral ekspresyon kasetinin canli atenüe YFV-17D'nin bir cDNA'sinni içermesi, burada bir veya daha fazla iliskisiz cDNA sekanslarinin viral poliprotein içinde bir ya da daha fazla heterolog protein olarak eksprese edilmek üzere eklenmesi veya burada söz konusu Viral ekspresyon kasetinin bir viral CDNA içermesi, burada yabanci cDNA sekanslarinin söz konusu rekombinant virüsler tarafindan heterolog olarak eksprese edilmek üzere eklenmesidir.
12. RNA virüslerine karsi bir asi hazirlamaya iliskin bir yöntem Olup, Özelligi; a) asagidakileri içeren bir BAC ile transfeksiyona ugrayan bir - söz konusu BAC'in bakteri hücresi basina lO'dan fazla kopyaya amplifikasyonu için bir indüklenebilir bakteriyel ori sekansi ve - bir atenüe RNA virüsü genomunun bir cDNA'sini içeren ve memeli hücrelerinde söz konusu Viral cDNA'nin çis-regülatör elemanlarini içern ve transkribe edilmis RNA'nin bulasici viral RNA virüsüne islenmesi için bir viral ekspresyon kaseti, b) söz konusu indüklenebilir` oriyi indükleyen bir bilesigin eklenmesi vasitasiyla BAC'in amplifiye edilmesine c) amplifiye edilmis BAC'in izole edilmesine d) BAC'in bir asi olarak formüle edilmesine iliskin adimlari içermesidir.
13. Bir RNA Virüs enfeksiyonunun engellenmesinde kullanima yönelik bir bakteriyel yapay kromozom (BAC) olup, özelligi; - söz konusu BAC'in bakteri hücresi basina lO'dan fazla kopyaya amplifikasyonu için bir indüklenebilir bakteriyel ori sekansi ve - bir atenüe RNA virüsü genomunun bir cDNA'sini içeren bir viral ekspresyon kaseti veya - bir atenüe RNA virüsü genomunun bir cDNA'sini içeren ve memeli hücrelerinde söz konusu viral cDNA'nin cis-regülatör elemanlarini içern ve transkribe edilmis RNA'nin bulasici Viral RNA virüsüne islenmesi için bir viral ekspresyon kaseti içermesidir.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1307528.8A GB201307528D0 (en) | 2013-04-26 | 2013-04-26 | Bacterial artificial chromosomes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201904215T4 true TR201904215T4 (tr) | 2019-04-22 |
Family
ID=48626864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/04215T TR201904215T4 (tr) | 2013-04-26 | 2014-04-25 | Bakteriyel yapay kromozomlar. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10076564B2 (tr) |
| EP (2) | EP2989205B1 (tr) |
| JP (1) | JP6501756B2 (tr) |
| KR (1) | KR102170609B1 (tr) |
| CN (1) | CN105229153A (tr) |
| AU (1) | AU2014259354B2 (tr) |
| BR (1) | BR112015026531B1 (tr) |
| DK (1) | DK2989205T3 (tr) |
| ES (1) | ES2718187T3 (tr) |
| GB (1) | GB201307528D0 (tr) |
| HU (1) | HUE042886T2 (tr) |
| PL (1) | PL2989205T3 (tr) |
| PT (1) | PT2989205T (tr) |
| SI (1) | SI2989205T1 (tr) |
| TR (1) | TR201904215T4 (tr) |
| WO (1) | WO2014174078A1 (tr) |
| ZA (1) | ZA201507795B (tr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201716254D0 (en) | 2017-10-05 | 2017-11-22 | Univ Leuven Kath | Live-attenuated flaviruses with heterologous antigens |
| GB201716307D0 (en) | 2017-10-05 | 2017-11-22 | Univ Leuven Kath | Chimeric yellow fever zika virus strain |
| US11254953B2 (en) * | 2018-04-18 | 2022-02-22 | Utah State University | Compositions and methods for zika virus characterization and vaccine development |
| GB201814563D0 (en) * | 2018-09-07 | 2018-10-24 | Univ Leuven Kath | Chimeric flavivirus lyssavirus vaccines |
| MX2021012424A (es) | 2019-04-10 | 2022-02-10 | Univ Leuven Kath | Virus quimérico de zika-encefalitis japonesa. |
| CN114728054A (zh) | 2019-09-13 | 2022-07-08 | 勒芬天主教大学 | 拉沙病毒疫苗 |
| EP4041301A1 (en) | 2019-09-13 | 2022-08-17 | Katholieke Universiteit Leuven | Chimeric filovirus vaccines |
| EP4034662A1 (en) | 2019-09-25 | 2022-08-03 | Katholieke Universiteit Leuven, K.U.Leuven R&D | Large vectors and methods for high-yield production |
| WO2021170869A1 (en) | 2020-02-27 | 2021-09-02 | Katholieke Universiteit Leuven | Coronavirus vaccines |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5665600A (en) | 1991-09-18 | 1997-09-09 | Research Corporation Technologies, Inc. | Pichia pastoris linear plasmids and DNA fragments thereof |
| US5866404A (en) | 1995-12-06 | 1999-02-02 | Yale University | Yeast-bacteria shuttle vector |
| US6962708B1 (en) | 1997-02-28 | 2005-11-08 | Acambis, Inc. | Chimeric flavivirus vaccines |
| US5874259A (en) | 1997-11-21 | 1999-02-23 | Wisconsin Alumni Research Foundation | Conditionally amplifiable BAC vector |
| EP1153136A2 (en) | 1998-12-09 | 2001-11-14 | The General Hospital Corporation | Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors |
| ES2170622B1 (es) | 1999-12-03 | 2004-05-16 | Consejo Superior De Investigaciones Cientificas | Clones y vectores infectivos derivados de coronavirus y sus aplicaciones. |
| GB2372991B (en) * | 2001-03-09 | 2004-11-17 | Fiocruz Fundacao Oswaldo Cruz | Flavivirus expression vector |
| US6472177B1 (en) | 2001-04-23 | 2002-10-29 | Wisconsin Alumni Research Foundation | Expression vector with dual control of replication and transcription |
| US6864087B2 (en) * | 2001-07-31 | 2005-03-08 | Wisconsin Alumni Research Foundation | Method for converting single-copy BAC vectors to conditional high-copy pBAC/oriHC vectors |
| US20050106733A1 (en) | 2001-12-25 | 2005-05-19 | Kenzo Takada | Double-stranded cyclic dna capable of proliferating as a bacterial e coli chromosome |
| WO2004033633A2 (en) | 2002-10-04 | 2004-04-22 | Embiosis Pharmaceuticals | Compatible host/vector systems for expression of dna |
| WO2005042014A1 (en) | 2003-10-29 | 2005-05-12 | The University Of Queensland | West nile virus vaccine |
| US20050214838A1 (en) | 2004-03-10 | 2005-09-29 | Waclaw Szybalski | Methods for mapping and sequencing nucleic acids |
| WO2009053988A1 (en) | 2007-10-25 | 2009-04-30 | Ramot At Tel-Aviv University Ltd. | Production of bac vectors carrying viral genomes |
| CN101864442A (zh) * | 2010-05-19 | 2010-10-20 | 江苏省农业科学院 | 重组火鸡疱疹病毒细菌人工染色体转移载体 |
-
2013
- 2013-04-26 GB GBGB1307528.8A patent/GB201307528D0/en not_active Ceased
-
2014
- 2014-04-25 PT PT14724009T patent/PT2989205T/pt unknown
- 2014-04-25 US US14/787,098 patent/US10076564B2/en active Active
- 2014-04-25 BR BR112015026531-6A patent/BR112015026531B1/pt active IP Right Grant
- 2014-04-25 TR TR2019/04215T patent/TR201904215T4/tr unknown
- 2014-04-25 KR KR1020157033335A patent/KR102170609B1/ko active IP Right Grant
- 2014-04-25 CN CN201480023688.3A patent/CN105229153A/zh active Pending
- 2014-04-25 ES ES14724009T patent/ES2718187T3/es active Active
- 2014-04-25 SI SI201431153T patent/SI2989205T1/sl unknown
- 2014-04-25 PL PL14724009T patent/PL2989205T3/pl unknown
- 2014-04-25 HU HUE14724009A patent/HUE042886T2/hu unknown
- 2014-04-25 EP EP14724009.7A patent/EP2989205B1/en active Active
- 2014-04-25 AU AU2014259354A patent/AU2014259354B2/en active Active
- 2014-04-25 EP EP18215987.1A patent/EP3540065A1/en not_active Withdrawn
- 2014-04-25 DK DK14724009.7T patent/DK2989205T3/en active
- 2014-04-25 WO PCT/EP2014/058459 patent/WO2014174078A1/en active Application Filing
- 2014-04-25 JP JP2016509489A patent/JP6501756B2/ja active Active
-
2015
- 2015-10-19 ZA ZA2015/07795A patent/ZA201507795B/en unknown
-
2018
- 2018-09-17 US US16/132,862 patent/US20190111125A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20160206723A1 (en) | 2016-07-21 |
| CN105229153A (zh) | 2016-01-06 |
| AU2014259354A1 (en) | 2015-11-05 |
| KR20160003032A (ko) | 2016-01-08 |
| EP2989205B1 (en) | 2019-01-02 |
| DK2989205T3 (en) | 2019-04-23 |
| PT2989205T (pt) | 2019-04-23 |
| JP2016518132A (ja) | 2016-06-23 |
| HUE042886T2 (hu) | 2019-07-29 |
| ZA201507795B (en) | 2019-07-31 |
| US10076564B2 (en) | 2018-09-18 |
| WO2014174078A1 (en) | 2014-10-30 |
| EP3540065A1 (en) | 2019-09-18 |
| GB201307528D0 (en) | 2013-06-12 |
| AU2014259354B2 (en) | 2020-02-27 |
| JP6501756B2 (ja) | 2019-04-17 |
| US20190111125A1 (en) | 2019-04-18 |
| SI2989205T1 (sl) | 2019-05-31 |
| ES2718187T3 (es) | 2019-06-28 |
| BR112015026531A2 (tr) | 2017-09-05 |
| EP2989205A1 (en) | 2016-03-02 |
| BR112015026531B1 (pt) | 2023-02-07 |
| KR102170609B1 (ko) | 2020-10-28 |
| PL2989205T3 (pl) | 2019-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201904215T4 (tr) | Bakteriyel yapay kromozomlar. | |
| Willemsen et al. | On the stability of sequences inserted into viral genomes | |
| Huang et al. | Capped RNA transcripts of full-length cDNA clones of swine hepatitis E virus are replication competent when transfected into Huh7 cells and infectious when intrahepatically inoculated into pigs | |
| EP1930416B1 (en) | Novel recombinant human hepatitis c virus-like particle and method for producing the same | |
| CN107937438B (zh) | 携带海肾荧光素酶的鸭坦布苏病毒瞬时转染复制子及其构建方法和应用 | |
| RU2012140691A (ru) | Вакцины на основе неинтегрирующегося ретровирусного вектора | |
| JP2010526542A5 (tr) | ||
| Atasheva et al. | Pseudoinfectious Venezuelan equine encephalitis virus: a new means of alphavirus attenuation | |
| JP6747983B2 (ja) | 感染性ｒｎａウイルスを迅速に生成するための方法 | |
| Li et al. | Efficient and stable rescue of classical swine fever virus from cloned cDNA using an RNA polymerase II system | |
| CN110468155B (zh) | 一种用于拯救猪肠道甲型冠状病毒的系统、方法及应用 | |
| Nickols et al. | Plasmid DNA launches live-attenuated Japanese encephalitis virus and elicits virus-neutralizing antibodies in BALB/c mice | |
| Wang et al. | A novel viral vaccine platform based on engineered transfer RNA | |
| CN108315306B (zh) | 一株高繁殖能力猪瘟病毒及其构建方法 | |
| JP2019535291A (ja) | プラス鎖ｒｎａウイルスによって引き起こされる感染疾患に対するワクチン | |
| Dalmann et al. | Autonomously replicating RNAs of Bungowannah pestivirus: ERNS is not essential for the generation of infectious particles | |
| CN113736799B (zh) | 山羊副流感病毒3型感染性cDNA克隆构建方法及其应用 | |
| Zheng et al. | Development of a hamster kidney cell line expressing stably T7 RNA polymerase using retroviral gene transfer technology for efficient rescue of infectious foot-and-mouth disease virus | |
| CN115433741A (zh) | 盖他病毒为载体表达报告蛋白的重组病毒的构建方法 | |
| JP2008546399A5 (tr) | ||
| WO2008024413A3 (en) | Tissue culture system for production of hepatitis c virus | |
| Silva Jr et al. | Efficient assembly of full-length infectious clone of Brazilian IBDV isolate by homologous recombination in yeast | |
| Keyer et al. | Towards development of plasmacytoma cells-based expression systems utilizing alphavirus vectors: An NS0-VEE model | |
| CN117106735B (zh) | 一种尼巴病毒的重组病毒载体、假病毒及其制备方法和应用 | |
| Hu et al. | Generation of duck Tembusu virus using a simple reverse genetic system in duck embryo fibroblast cells |